19/03/2021at 15:40

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Top news from MedWatch this week
For subscribers
Top news from MedWatch this week
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Regulation

CHMP recommends four drugs in January

Bristol Myers Squibb’s Sotyktu, a treatment for moderate-to-severe psoriasis in adults, has gained the favor of the EMA’s expert committee, alongside three generics.

For subscribers

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri

Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

For subscribers

Maiken Riise Andersen, ALK's new head of communications and media relations | Foto: Jørgen True, Studie-e

Pharma & biotech

New ALK head of communications to draw in new hires

For subscribers

Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

Other

Top news from MedWatch this week

EMA's hovedkvarter i Amsterdam. | Foto: Rob Acket/ema

Pharma & biotech

EMA says antibiotic shortage situation isn't "major event"

For subscribers

Coloplast is the world's most sustainable medtech firm in new analysis

Among 87 of the largest, publicly listed medtech companies, Coloplast has been deemed the very best on sustainability, according to a new international ranking.

For subscribers

Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

When GN Group’s chair retires following the company’s next AGM, it could pave the way for a large consolidation within the Danish hearing aid market, an analyst says.

For subscribers

Pharma & biotech

FDA approves Novo Nordisk's Rybelsus as first-line treatment option

Rybelsus, the tablet formulation of semaglutide, has now been approved in the US as a first-line treatment option for adults with type 2 diabetes.

For subscribers

Latest news

See all

Jobs

See all jobs

Jobs

See all jobs

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Top news from MedWatch this week

Monday

Read the whole article

With your free trial you get:

Get full access for you and your coworkers

Related articles:

Top news from MedWatch this week

Top news from MedWatch this week

Sign up for our newsletter

Front page now

CHMP recommends four drugs in January

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

New ALK head of communications to draw in new hires

Analyst: Chairman exit increases chance of GN-Demant merger

Top news from MedWatch this week

EMA says antibiotic shortage situation isn't "major event"

Further reading

Coloplast is the world's most sustainable medtech firm in new analysis

Analyst: Chairman exit increases chance of GN-Demant merger

FDA approves Novo Nordisk's Rybelsus as first-line treatment option

Latest news

Jobs

Jobs